| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
Revenue  | 754 | 831 | 871 | 823 | 819 | 1,299 | 795 | 803 | 707 | 888 | 834 | 785 | 764 | 964 | 838 | 2,132 | 776 | 939 | 826 | 826 | 815 | 985 | 833 | 962 | 850 | 1,050 | 985 | 1,015 |
| Expenses | 608 | 663 | 688 | 588 | 623 | 688 | 1,408 | 602 | 535 | 739 | 611 | 707 | 586 | 678 | 636 | 634 | 596 | 660 | 585 | 618 | 618 | 668 | 751 | 673 | 584 | 689 | 658 | 641 |
| EBITDA | 145 | 168 | 183 | 236 | 196 | 611 | -613 | 201 | 172 | 150 | 223 | 78 | 178 | 286 | 202 | 1,497 | 180 | 279 | 241 | 208 | 198 | 318 | 83 | 290 | 266 | 361 | 327 | 374 |
| Operating Profit % | 17 % | 19 % | 17 % | 22 % | 21 % | 22 % | -81 % | 22 % | 18 % | 16 % | 23 % | 5 % | 18 % | 27 % | 22 % | 22 % | 20 % | 28 % | 27 % | 22 % | 19 % | 30 % | 7 % | 28 % | 28 % | 32 % | 31 % | 34 % |
| Depreciation | 11 | 12 | 12 | 14 | 19 | 23 | 18 | 23 | 22 | 22 | 18 | 18 | 18 | 17 | 18 | 15 | 16 | 16 | 16 | 17 | 16 | 18 | 17 | 18 | 16 | 17 | 19 | 15 |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Profit Before Tax | 134 | 157 | 171 | 222 | 176 | 587 | -634 | 177 | 149 | 127 | 204 | 60 | 160 | 268 | 184 | 1,482 | 163 | 262 | 224 | 190 | 181 | 299 | 65 | 271 | 249 | 344 | 308 | 359 |
| Tax | 50 | 56 | 57 | 75 | 63 | 85 | 27 | 39 | 38 | 51 | 48 | 45 | 39 | 64 | 34 | 263 | 44 | 69 | 60 | 57 | 49 | 82 | 20 | 76 | 67 | 91 | 78 | 96 |
| Net Profit | 84 | 101 | 114 | 147 | 114 | 503 | -661 | 138 | 111 | 77 | 157 | 14 | 121 | 204 | 150 | 1,219 | 119 | 193 | 165 | 133 | 132 | 218 | 46 | 195 | 182 | 253 | 230 | 263 |
| EPS in ₹ | 9.93 | 5.95 | 6.71 | 8.67 | 6.70 | 29.68 | -39.03 | 8.15 | 6.54 | 4.51 | 10.26 | 0.85 | 7.14 | 12.06 | 8.87 | 71.96 | 7.04 | 11.42 | 9.71 | 7.41 | 7.04 | 12.84 | 9.89 | 11.37 | 10.76 | 14.67 | 13.57 | 15.52 |
GlaxoSmithKline Pharmaceuticals
GlaxoSmithKline Pharmaceuticals
3,150.20
+66.70
(2.16%)
There are new updates from the company1 day ago
View
Market Cap
52,236.40 Cr
EPS
54.76
PE Ratio
59.87
Dividend Yield
1.75 %
Industry
Healthcare52 Week High
3,515.70
52 Week Low
1,921.00
PB Ratio
26.82
Debt to Equity
0.01
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from4 analysts
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,710.50 | #1 4,08,414.80 | 35.66 | #1 54,729.00 | 12.06 | #1 10,980 | -18.99 | 58.60 | |
6,676.50 | 1,74,784.50 | 79.73 | 9,712.00 | 0.89 | 2,191 | 23.05 | 48.64 | |
1,574.00 | 1,26,971.70 | 23.53 | 28,409.50 | 7.12 | 5,291 | 9.88 | 71.10 | |
3,768.10 | 1,22,615.40 | 60.75 | 11,539.40 | 6.99 | 1,911 | 19.91 | 79.03 | |
1,299.80 | 1,07,442.70 | #1 18.90 | 33,741.20 | 16.73 | 5,725 | 1.26 | 58.16 | |
2,554.70 | 1,04,899.10 | 60.41 | 12,744.20 | 19.57 | 2,007 | -10.91 | 53.75 | |
994.85 | 98,621.00 | 21.20 | 23,511.00 | 13.82 | 4,615 | -0.19 | 61.13 | |
1,984.60 | 89,535.10 | 27.57 | 22,909.50 | #1 19.94 | 3,306 | #1 112.49 | 58.19 | |
34,710.00 | 69,899.60 | 49.39 | 6,684.70 | 10.80 | 1,414 | 27.83 | 57.75 | |
1,158.10 | 65,456.30 | 18.95 | 31,378.10 | 17.55 | 3,366 | -0.50 | 55.90 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
8.91 %
Net Income Growth
57.22 %
Cash Flow Change
121.62 %
ROE
43.24 %
ROCE
42.20 %
EBITDA Margin (Avg.)
17.79 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 3,216 | 3,055 | 3,004 | 3,948 | 3,911 | 3,136 | 3,115 | 4,633 | 3,327 | 3,557 | 4,108 |
| Fixed Assets | 123 | 210 | 258 | 325 | 432 | 758 | 387 | 331 | 330 | 321 | 284 |
| Current Assets | 2,587 | 2,174 | 1,674 | 2,186 | 2,010 | 1,775 | 2,203 | 3,708 | 2,494 | 2,798 | 3,410 |
| Capital Work in Progress | 115 | 268 | 606 | 923 | 1,003 | 120 | 13 | 31 | 20 | 14 | 14 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 366 | 518 | 813 | 1,118 |
| Other Assets | 2,977 | 2,577 | 2,140 | 2,700 | 2,477 | 2,257 | 2,715 | 3,907 | 2,458 | 2,408 | 2,692 |
| Total Liabilities | 3,216 | 3,055 | 3,004 | 3,948 | 3,911 | 3,136 | 3,115 | 4,633 | 3,327 | 3,557 | 4,108 |
| Current Liabilities | 1,107 | 579 | 720 | 1,600 | 1,454 | 1,024 | 1,355 | 1,698 | 1,326 | 1,525 | 1,905 |
| Non Current Liabilities | 280 | 292 | 277 | 290 | 317 | 291 | 282 | 272 | 259 | 254 | 252 |
| Total Equity | 1,829 | 2,183 | 2,007 | 2,057 | 2,140 | 1,821 | 1,478 | 2,663 | 1,741 | 1,778 | 1,951 |
| Reserve & Surplus | 1,744 | 2,099 | 1,922 | 1,973 | 1,970 | 1,651 | 1,309 | 2,494 | 1,572 | 1,608 | 1,782 |
| Share Capital | 85 | 85 | 85 | 85 | 169 | 169 | 169 | 169 | 169 | 169 | 169 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 21 | -0 | 24 | 62 | -102 | 6 | 300 | -119 | -251 | 29 | 475 |
| Investing Activities | 180 | 499 | 301 | -104 | -153 | -57 | 418 | -406 | 808 | 9 | -46 |
| Operating Activities | 338 | 139 | 234 | 473 | 410 | 491 | 578 | 811 | 484 | 582 | 1,290 |
| Financing Activities | -497 | -638 | -511 | -307 | -358 | -428 | -696 | -524 | -1,543 | -562 | -769 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 3.48 % | 4.02 % | 4.36 % | 4.50 % | 4.52 % | 4.89 % |
| DIIs | 5.31 % | 5.51 % | 5.50 % | 5.61 % | 5.61 % | 4.08 % | 10.45 % | 10.28 % | 10.30 % | 10.23 % | 10.01 % | 8.53 % | 7.90 % | 7.50 % | 7.34 % | 7.30 % | 7.79 % | 7.70 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.01 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 11.02 % | 10.86 % | 10.83 % | 10.67 % | 10.41 % | 10.41 % | 10.40 % | 10.56 % | 10.54 % | 10.57 % | 10.62 % | 11.08 % | 11.27 % | 11.15 % | 10.97 % | 10.96 % | 10.60 % | 10.32 % |
| Others | 8.67 % | 8.62 % | 8.67 % | 8.73 % | 8.98 % | 10.51 % | 4.15 % | 4.16 % | 4.16 % | 4.20 % | 4.37 % | 5.38 % | 2.35 % | 2.33 % | 2.33 % | 2.23 % | 2.09 % | 2.09 % |
| No of Share Holders | 1,19,951 | 1,20,476 | 1,21,445 | 1,23,480 | 1,10,141 | 1,12,964 | 1,16,651 | 1,20,127 | 1,20,415 | 1,19,032 | 1,15,266 | 1,14,663 | 1,18,994 | 1,18,515 | 1,19,228 | 1,19,625 | 1,21,885 | 1,23,629 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 30 | 35 | 20 | 40 | 30 | 90 | 32 | 32 | 54 |
| Dividend Yield (%) | 0.00 | 2.87 | 2.7 | 1.59 | 2.78 | 1.8 | 7.05 | 1.64 | 1.11 | 1.75 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 01 Aug 2025 |  Quarterly Result Announcement | NA | 01 Aug 2025 | 3,262.85 | 3,083.50 |
| 27 Jun 2025 |  Annual General Meeting | NA | 27 Jun 2025 | 2,721.25 | 3,301.90 |
| 30 May 2025 |  Dividend | ₹ 42.00 /share | 30 May 2025 | 2,721.25 | 3,263.40 |
| 13 May 2025 | Quarterly Result Announcement | NA | 13 May 2025 | 2,928.60 | 2,721.25 |
| 14 Feb 2025 | Quarterly Result Announcement | NA | 14 Feb 2025 | 2,077.20 | 1,998.80 |
| 07 Nov 2024 | Dividend | ₹ 12.00 /share | 07 Nov 2024 | 2,644.65 | 2,632.20 |
| 29 Oct 2024 | Quarterly Result Announcement | NA | 29 Oct 2024 | 2,630.85 | 2,644.65 |
| 28 Jun 2024 | Annual General Meeting | NA | 28 Jun 2024 | 2,023.85 | 2,677.55 |
| 31 May 2024 | Dividend | ₹ 32.00 /share | 31 May 2024 | 2,023.85 | 2,593.00 |
| 30 Jun 2023 | Dividend | ₹ 32.00 /share | 30 Jun 2023 | 1,289.55 | 1,438.20 |
| 26 Jul 2022 | Annual General Meeting | NA | 26 Jul 2022 | 1,493.30 | 1,493.85 |
| 08 Jul 2022 | Dividend | ₹ 60.00 /share | 07 Jul 2022 | 1,493.30 | 1,505.90 |
| 08 Jul 2022 | Dividend | ₹ 30.00 /share | 07 Jul 2022 | 1,493.30 | 1,505.90 |
| 20 Jul 2021 | Dividend | ₹ 30.00 /share | 19 Jul 2021 | 1,518.15 | 1,607.55 |
| 13 Sept 2018 |  Bonus | 1:1 | 11 Sept 2018 | 1,726.60 | 1,724.70 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication6 days ago
6 days agoCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 11, 2025
Jul 11, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 09, 2025
Jul 09, 2025Board Meeting Intimation for Board Meeting Intimation
Jul 04, 2025
Jul 04, 2025Outcome Of AGMJun 27, 2025
Jun 27, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportJun 27, 2025
Jun 27, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMJun 27, 2025
Jun 27, 2025Disclosure Under Regulation 30Jun 27, 2025
Jun 27, 2025Closure of Trading WindowJun 26, 2025
Jun 26, 2025Analyst MeetJun 20, 2025
Jun 20, 2025Disclosure Under Regulation 30Jun 19, 2025
Jun 19, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 05, 2025
Jun 05, 2025Letter To Shareholders For Annual Report LinkJun 05, 2025
Jun 05, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 05, 2025
Jun 05, 2025100Th Annual General Meeting On 27Th June 2025Jun 03, 2025
Jun 03, 2025Business Responsibility and Sustainability Reporting (BRSR)Jun 03, 2025
Jun 03, 2025Reg. 34 (1) Annual Report.Jun 03, 2025
Jun 03, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJun 02, 2025
Jun 02, 2025Disclosure Under Regulation 30May 16, 2025
May 16, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 14, 2025
May 14, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 13, 2025
May 13, 2025Appointment Of Parikh & Associates As Secretarial Auditor Of The Company
May 13, 2025
May 13, 2025100Th Annual General Meeting On 27Th June 2025May 13, 2025
May 13, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateMay 13, 2025
May 13, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 13, 2025
May 13, 2025Announcement under Regulation 30 (LODR)-Dividend UpdatesMay 13, 2025
May 13, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 13, 2025
May 13, 2025Record Date For Final Dividend 30Th May 2025May 13, 2025
May 13, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 13, 2025
May 13, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 13, 2025
May 13, 2025Corporate Action-Board approves DividendMay 13, 2025
May 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 13, 2025
May 13, 2025Outcome Of MeetingMay 13, 2025
May 13, 2025Board Meeting Outcome for Outcome Of MeetingMay 13, 2025
May 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 08, 2025
May 08, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 02, 2025
May 02, 2025Disclosure Under Regulation 30Apr 29, 2025
Apr 29, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotApr 29, 2025
Apr 29, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportApr 29, 2025
Apr 29, 2025Increase In VolumesApr 25, 2025
Apr 25, 2025Increase In VolumesApr 25, 2025
Apr 25, 2025Board Meeting Intimation for Approval Of Audited Financial Results (Standalone & Consolidated) For The Quarter / Year Ended 31St March 2025Apr 17, 2025
Apr 17, 2025Disclosure Under Regulation 30Apr 11, 2025
Apr 11, 2025Disclosure Under Regulation 30Apr 09, 2025
Apr 09, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 04, 2025
Apr 04, 2025Announcement under Regulation 30 (LODR)-Change in ManagementApr 04, 2025
Apr 04, 2025Technical Indicators
RSI(14)
Neutral 38.54
ATR(14)
Volatile 87.19
STOCH(9,6)
Neutral 21.71
STOCH RSI(14)
Oversold 14.52
MACD(12,26)
Bearish -16.50
ADX(14)
Weak Trend 19.56
UO(9)
Bearish 34.18
ROC(12)
Downtrend But Slowing Down -5.18
WillR(14)
Oversold -95.95
Mutual Fund Holdings
SBI Mid Cap Direct Plan-Growth 
Aditya Birla Sun Life ELSS Tax Saver Direct-Growth 
Edelweiss Balanced Advantage Fund Direct-Growth 
Bandhan ELSS Tax Saver Fund Direct Plan-Growth 
Tata Nifty Midcap 150 Momentum 50 Index Fund Direct - Growth 
JM Midcap Fund Direct - Growth 
Nippon India Pharma Fund Direct-Growth 
Union Active Momentum Fund Direct-Growth 
Motilal Oswal Nifty 500 Momentum 50 Index Fund Direct-Growth 
Bajaj Finserv Flexi Cap Fund Direct-Growth 
Kotak Nifty Midcap 150 Momentum 50 Index Fund Direct-Growth 
DSP Nifty Midcap 150 Quality 50 Index Fund Direct - Growth 
Samco Flexi Cap Fund Direct - Growth About GlaxoSmithKline Pharmaceuticals
GlaxoSmithKline Pharmaceuticals Limited is an Indian subsidiary of UK-based GSK Plc, engaged in manufacturing, distributing, and trading pharmaceuticals. The company operates in three main product areas: vaccines, specialty medicines, and general medicines. It has manufacturing facilities in Nashik and Thane, with a clinical development center in Bangalore. The company's portfolio includes medicines for various therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease, and respiratory diseases. They also offer a range of vaccines for various diseases. Key brands include Augmentin, Calpol, Shingrix, Nucala, and Trelegy Ellipta. The company has six branch offices and works with 22 contract manufacturing organizations across India. A new manufacturing facility is being developed in Vemgal, Karnataka, with an investment of over Rs 1000 crore.
Website
Chairperson NameRenu S Karnad
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
